Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Thoratec Seeks Less Invasive VAD Access With Apica Acquisition

This article was originally published in The Gray Sheet

Executive Summary

The completed deal calls for $35 million up front and $40 million in future clinical and sales milestones. Apica is developing systems to assist transapical surgical access for ventricular assist devices and transcatheter valve replacements.

You may also be interested in...



Thoratec Looks To Next-Generation LVADs To Revive Sinking Sales

Thoratec reported a near 10 percent year-over-year decline in revenue in the second quarter; physicians have become more selective about which patients to implant with a HeartMate II ventricular assist device, the firm says. The company is looking to next-generation of HeartMate products as well as the technology it acquired in the Apica deal to help it return to growth.

Apica Cardiovascular Ltd.

Apica Cardiovascular is leading the field of transapical access and closure for structural heart disease. Its first product is a titanium coil that stabilizes the surgical access site in the apex of the heart to prevent bleeding during and after therapeutic interventions and provides for reaccess in the future. Also in the works are a large closure device for transfemoral access closure and a connector that aids in the delivery and implantation of newer, smaller, left ventricular assist devices through the Apica coil.

Can Can-Fite’s Piclidenoson Put Up A Fight In Psoriasis?

Can-Fite’s A3AR agonist was inferior to Amgen’s Otezla by most efficacy measures, while Bristol Myers Squibb’s competing deucravacitinib is closer to approval and did beat Otezla.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

MT033133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel